The FDA has approved Roche’s Rozlytrek (entrectinib), a so-called “tumour agnostic” drug that is approved to key into certain mutations in cancer, instead of where the disease originates. <
Bayer has announced it is fully acquiring US cell therapy biotech BlueRock Therapeutics, whose cell therapy pipeline includes a treatment for Parkinson’s disease.
Bayer’s Xarelto (rivaroxaban) can be funded by the NHS to prevent strokes and heart attacks in high-risk adults with coronary artery disease, NICE has said.
The FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease as it takes on rivals such as Johnson & Johnson.
